Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (GB:0HFR)
LSE:0HFR
0HFR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.30 - $14.45
Previous CloseN/A
Volume26.29K
Average Volume (3M)4.68K
Market Cap
$753.67M
Enterprise Value$349.45M
Total Cash (Recent Filing)$423.78K
Total Debt (Recent Filing)$200.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 08, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding85,064,200
10 Day Avg. Volume4,064
30 Day Avg. Volume4,682
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-17.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.80
Forecast
1Y Price Target
$28.50Price Target Upside201.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityEuropean market opportunity for blarcamesine could be highly lucrative, with almost 8 million people in Europe affected by Alzheimer’s disease.
Therapeutic BenefitsBlarcamesine open-label extension four-year data underscore potential therapeutic benefits in Alzheimer's disease.
Bears Say
Regulatory ConcernsEuropean and UK regulatory resistance to anti-amyloid antibodies reflects concerns around their risk-benefit profile and lack of imaging facilities for monitoring ARIA risk.
Risk FactorsRisks include, but are not limited to: negative clinical data with blarcamesine in AD, PDD and Rett syndrome; failure to obtain approval for blarcamesine across its target indications; inability to launch blarcamesine effectively; setbacks with other candidates; and possible long-term dilution risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.51% Insiders
8.42%
Mutual Funds
4.47% Other Institutional Investors
73.20% Public Companies and
Individual Investors
0HFR FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest share price was $3.30 and its highest was $14.45 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $753.67M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Feb 12, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.03.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 85,064,200 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -1.468%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in GB:0HFR
---
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.50 (201.27% Upside)
$28.50 (201.27% Upside)
Blogger Sentiment
Bullish
GB:0HFR Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.10%
12-Months-Change
Fundamentals
Return on Equity
-37.72%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
---
0HFR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The conference call highlighted significant progress in Alzheimer’s treatment development, including promising trial results and a new patent. Financial stability and strategic clinical trials were also emphasized. However, increased expenses, net losses, and delays in certain programs were noted as challenges. Overall, the sentiment is cautiously optimistic, reflecting both achievements and areas needing further clarity.Read More>---
0HFR Stock 12 Month Forecast
Average Price Target
$28.50
▲(201.27% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Cassava Sciences
―
Axsome Therapeutics
―
Adial Pharmaceuticals
―
Best Analysts Covering 0HFR
1 Year
1 Year Success Rate
16/26 ratings generated profit
1 Year Average Return
+93.46%
initiated a buy rating 9 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +93.46% per trade.
---